RxDoctor Payments Data

Carl Jacobsen

Optometrist · Berkeley, CANPI 1003941766

Payments from drug & device makers

$1,634in general payments, 2019–2025

Across 11 payments — averaging $148.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$928
  • Alcon$241
  • Aerie Pharmaceuticals, Inc.$199
  • Bausch & Lomb Americas Inc.$143
  • Novartis$96
  • Carl Zeiss Meditec, Inc.$27

What the payments were for

  • Consulting fees$80049%
  • Food & beverage$81750%
  • Education$181%

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,634 in reported general payments places this provider in the 70th percentile of 6,778 optometrist providers in California.

See all optometrist providers in California

Medicare billing

Part B allowed, 2024
$159,860
Medicare patients
681
Services billed
1,692

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RocklatanNetarsudil Mesylat/Latanoprost42$36,748
LumiganBimatoprost47$29,679
VyzultaLatanoprostene Bunod32$23,186
RhopressaNetarsudil Mesylate14$10,790
Brinzolamide38$7,972
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol24$5,779
Latanoprost270$4,399
Brimonidine Tartrate43$2,555
SimbrinzaBrinzolamide/Brimonidine Tart12$2,352
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat86$1,680
Dorzolamide Hcl39$1,000
Bimatoprost11$883
Prednisolone Acetate24$865
Timolol Maleate54$724
Ketorolac Tromethamine15$188

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$199$47,53956 claims
AbbVieLumigan$928$29,67947 claims
Bausch & Lomb Americas Inc.Vyzulta$143$23,18632 claims
AlconSimbrinza$241$2,35212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 6,778 optometrist providers in California.

Other optometrist in Berkeley

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →